{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:44:47Z","timestamp":1781131487148,"version":"3.54.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Despite evidence supporting efficacy of low-fluence Q-switched (QS) neodymium-doped yttrium aluminum garnet (Nd:YAG) 1,064-nm lasers, treatment protocols are not standardized and limited to mostly retrospective, observational, or inadequately controlled studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To investigate the safety and efficacy of low-fluence QS Nd:YAG (1,064 nm) laser in the treatment of melasma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>A prospective, blind, randomized, placebo-controlled split face trial was conducted. Patients with Fitzpatrick skin types I-IV, and melasma severity scores of at least 2 received 3 monthly treatments using mechanical exfoliation, low-fluence QS Nd:YAG laser, hydroquinone 4% twice daily, and sunscreen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Both treatment and control sides of the face showed a comparable decrease in melanin index (MI), with a statistically significant difference only after treatment 2 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .04). The Modified Melasma and Severity Index (mMASI) score for both the treatment and control decreased but without any significant difference (.18 &lt;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; .57). The highest level of patient-reported improvement occurred at week 8; however, patient-reported improvement decreased by the 6-month follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Placebo and laser treatment groups showed an effective, safe, yet similar decrease in both MI and mMASI scores, indicating that low-fluence, QS Nd:YAG laser treatments did not add significant benefit beyond combination topical therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dss.0000000000004846","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T12:01:30Z","timestamp":1757592090000},"page":"205-211","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of Melasma Using Low-Fluence QS Nd: YAG (1064 nm) Laser: A Blind, Randomized, Placebo-Controlled Trial"],"prefix":"10.1097","volume":"52","author":[{"given":"Mona","family":"Sadeghpour","sequence":"first","affiliation":[{"name":"Department of Dermatology, New York University, New York City, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Laughter","sequence":"additional","affiliation":[{"name":"Department of Dermatology, New York University, New York City, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Ionto","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Ora Inc., Andover, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaninha","family":"Depina","sequence":"additional","affiliation":[{"name":"SkinCare Physicians, Chestnut Hill, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Petrell","sequence":"additional","affiliation":[{"name":"SkinCare Physicians, Chestnut Hill, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth A.","family":"Arndt","sequence":"additional","affiliation":[{"name":"SkinCare Physicians, Chestnut Hill, Massachusetts;"},{"name":"Department of Dermatology, Brown Medical School, Providence, Rhode Island;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Dover","sequence":"additional","affiliation":[{"name":"SkinCare Physicians, Chestnut Hill, Massachusetts;"},{"name":"Department of Dermatology, Brown Medical School, Providence, Rhode Island;"},{"name":"Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"R1-20260227","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.dad.0000154419.18653.2e","article-title":"Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma","volume":"27","author":"Grimes","year":"2005","journal-title":"Am J Dermatopathol"},{"key":"R2-20260227","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jaad.2006.02.009","article-title":"The treatment of melasma: a review of clinical trials","volume":"55","author":"Gupta","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R3-20260227","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0190-9622(81)70071-9","article-title":"Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study","volume":"4","author":"Sanchez","year":"1981","journal-title":"J Am Acad Dermatol"},{"key":"R4-20260227","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/14764172.2016.1229485","article-title":"Energy-based device treatment of melasma: an update and review of the literature","volume":"19","author":"Dunbar","year":"2017","journal-title":"J Cosmet Laser Ther"},{"key":"R5-20260227","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.sder.2012.02.002","article-title":"The evolution of melasma therapy: targeting melanosomes using low-fluence Q-Switched neodymium-doped yttrium aluminium garnet lasers","volume":"31","author":"Kauvar","year":"2012","journal-title":"Semin Cutan Med Surg"},{"key":"R6-20260227","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1097\/DSS.0000000000001164","article-title":"Commentary on the clinical and histological effect of a low-fluence Q-Switched 1,064-nm neodymium dermatologic surg","volume":"43","author":"Kauvar","year":"2017","journal-title":"Dermatol Surg"},{"key":"R7-20260227","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1038\/jid.2010.129","article-title":"Subcellular selective photothermolysis of melanosomes in adult zebrafish skin following 1064-nm Q-switched Nd:YAG laser irradiation","volume":"130","author":"Kim","year":"2010","journal-title":"J Invest Dermatol"},{"key":"R8-20260227","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jmicro\/dfq068","article-title":"A low fluence Q-switched Nd:YAG laser modifies the 3D structure of melanocyte and ultrastructure of melanosome by subcellular-selective photothermolysis","volume":"60","author":"Mun","year":"2011","journal-title":"J Electron Microsc (Tokyo)"},{"key":"R9-20260227","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3109\/14764172.2010.487910","article-title":"Treatment of refractory melasma with the MedLite C6 Q-switched Nd:YAG laser and alpha arbutin: a prospective study","volume":"12","author":"Polnikorn","year":"2010","journal-title":"J Cosmet Laser Ther"},{"key":"R10-20260227","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/09546631003686051","article-title":"Efficacy of the 1064-nm Q-switched Nd:YAG laser in melasma","volume":"22","author":"Suh","year":"2011","journal-title":"J Dermatolog Treat"},{"key":"R11-20260227","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1524-4725.2009.01383.x","article-title":"Low-fluence q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians","volume":"36","author":"Wattanakrai","year":"2010","journal-title":"Dermatol Surg"},{"key":"R12-20260227","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/DSS.0000000000000057","article-title":"Combination treatment of low-fluence 1,064-nm Q-switched nd: YAG laser with novel intense pulse light in Korean melasma patients: a prospective, randomized, controlled trial","volume":"40","author":"Yun","year":"2014","journal-title":"Dermatol Surg"},{"key":"R13-20260227","first-page":"1296","article-title":"The evolution of quality-switched lasers","volume":"11","author":"Saedi","year":"2012","journal-title":"J Drugs Dermatol JDD"},{"key":"R14-20260227","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3109\/14764172.2011.630084","article-title":"Treatment of melasma with low fluence, large spot size, 1064-nm Q-switched neodymium-doped yttrium aluminum garnet (Nd:YAG) laser for the treatment of melasma in Fitzpatrick skin types IIIV","volume":"13","author":"Brown","year":"2011","journal-title":"J Cosmet Laser Ther"},{"key":"R15-20260227","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/DSS.0000000000000653","article-title":"Clinical and histopathologic assessment of facial melasma after low-fluence q-switched neodymium-doped yttrium aluminium garnet laser","volume":"42","author":"Hofbauer Parra","year":"2016","journal-title":"Dermatol Surg"},{"key":"R16-20260227","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/lsm.20956","article-title":"A case series of facial depigmentation associated with low fluence Q-switched 1,064nm Nd:YAG laser for skin rejuvenation and melasma","volume":"42","author":"Chan","year":"2010","journal-title":"Lasers Surg Med"},{"key":"R17-20260227","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/lsm.21156","article-title":"Successful treatment of melasma using a combination of microdermabrasion and Q-switched Nd:YAG lasers","volume":"44","author":"Kauvar","year":"2012","journal-title":"Lasers Surg Med"},{"key":"R18-20260227","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4103\/0974-2077.104915","article-title":"A comparison of low-fluence 1064-nm Q-switched Nd: YAG laser with topical 20% azelaic acid cream and their combination in melasma in Indian patients","volume":"5","author":"Bansal","year":"2012","journal-title":"J Cutan Aesthet Surg"},{"key":"R19-20260227","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaad.2014.08.023","article-title":"Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial","volume":"72","author":"Boukari","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R20-20260227","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jaad.2009.10.051","article-title":"Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method","volume":"64","author":"Pandya","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R21-20260227","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.yacs.2018.02.008","article-title":"Advances in the treatment of melasma","volume":"1","author":"Sadeghpour","year":"2018","journal-title":"Adv Cosmet Surg"},{"key":"R22-20260227","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1365-2230.2011.04150.x","article-title":"A randomized, observer-blinded, comparison of combined 1064-nm Q-switched neodymium-doped yttrium-aluminium-garnet laser plus 30% glycolic acid peel vs. laser monotherapy to treat melasma","volume":"36","author":"Park","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"R23-20260227","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09546630050517333","article-title":"A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma","volume":"11","author":"Ennes","year":"2000","journal-title":"J Dermatol Treat"},{"key":"R24-20260227","first-page":"92","article-title":"The efficacy of a broad-spectrum sunscreen in the treatment of melasma","volume":"83","author":"Vazquez","year":"1983","journal-title":"Cutis"},{"key":"R25-20260227","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/0974-2077.99436","article-title":"Lasers for treatment of melasma and post-inflammatory hyperpigmentation","volume":"5","author":"Arora","year":"2012","journal-title":"J Cutan Aesthet Surg"},{"key":"R26-20260227","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.2147\/CCID.S385162","article-title":"Post-inflammatory hyperpigmentation in dark skin: molecular mechanism and skincare implications","volume":"15","author":"Markiewicz","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:02:34Z","timestamp":1772200954000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000004846","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]}}}